{
    "clinical_study": {
        "@rank": "63964", 
        "brief_summary": {
            "textblock": "PRIMARY: To assess the safety of nimodipine in the treatment of HIV-Associated Motor /\n      Cognitive Complex (formerly AIDS dementia complex). To assess the systemic or central\n      nervous system toxicities (e.g., rash, headache, gastrointestinal symptoms, nausea, dyspnea,\n      muscle pain or cramp, acne) of nimodipine.\n\n      SECONDARY: To assess the efficacy of nimodipine in stabilizing the progression of\n      HIV-Associated Motor / Cognitive Complex by improvement in neuropsychological test\n      performance, peripheral neuropathy, or other neurologic manifestations.\n\n      HIV-infected patients may develop a condition known as HIV-Associated Motor / Cognitive\n      Complex (also known as AIDS dementia complex) that causes damage to the nervous system,\n      particularly the brain and spinal cord. Evidence exists that nimodipine protects nerve cells\n      in culture from injury by HIV. Although nimodipine has been used in patients with other\n      neurological problems, its safety and effectiveness in halting the progression of\n      HIV-Associated Motor / Cognitive Complex is not yet known."
        }, 
        "brief_title": "Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1", 
        "completion_date": {
            "#text": "June 1994", 
            "@type": "Actual"
        }, 
        "condition": [
            "AIDS Dementia Complex", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "AIDS Dementia Complex", 
                "Dementia", 
                "Neurologic Manifestations"
            ]
        }, 
        "detailed_description": {
            "textblock": "HIV-infected patients may develop a condition known as HIV-Associated Motor / Cognitive\n      Complex (also known as AIDS dementia complex) that causes damage to the nervous system,\n      particularly the brain and spinal cord. Evidence exists that nimodipine protects nerve cells\n      in culture from injury by HIV. Although nimodipine has been used in patients with other\n      neurological problems, its safety and effectiveness in halting the progression of\n      HIV-Associated Motor / Cognitive Complex is not yet known.\n\n      Forty patients currently taking zidovudine (AZT) or any other approved antiretroviral agent\n      will be randomized to one of three treatment arms: high-dose nimodipine, low-dose\n      nimodipine, or placebo.  Additionally, six patients who are intolerant to standard\n      antiretroviral therapy will be randomized to receive high- or low-dose nimodipine.\n      Nimodipine is administered by mouth concurrently with patients' prestudy dose of\n      antiretroviral agent. Treatment is given for 16 weeks, and patients are followed every 4\n      weeks. As an option, all patients may receive an additional 16 weeks of low-dose nimodipine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Alternative or additional antiretroviral agents if on a stable dose for 8 weeks prior\n             to study entry.\n\n          -  Isoniazid.\n\n          -  Anticonvulsants.\n\n          -  Benzodiazepines and antidepressants (provided dose is stable prior to study entry).\n\n          -  Symptomatic therapies (e.g., analgesics, antihistamines, antiemetics, and\n             antidiarrheal agents).\n\n          -  Maintenance therapy with clarithromycin, azithromycin, amikacin, ethambutol,\n             clofazimine, ciprofloxacin, and rifampin for disseminated Mycobacterium avium\n             infection.\n\n          -  Maintenance therapy for opportunistic infections (e.g., PCP, MAI, CMV).\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  HIV-Associated Motor / Cognitive Complex.\n\n          -  Acceptable neurological and neuropsychological impairment scores.\n\n          -  Estimated premorbid IQ of 70 or greater, consistent with completion of the sixth\n             grade or ability to read at the sixth grade level. Current ability to read and\n             comprehend a newspaper or history of such ability will satisfy this criterion for\n             patients whose formal education stopped before the sixth grade. For patients who are\n             illiterate, ability to make change from a dollar for a combined purchase of two items\n             or the history of such ability will satisfy this criterion. In the absence of a\n             functional definition, an age-correlated scaled score of > 5 on the Vocabulary\n             Subtest of the WAIS-R or WISC-R may be used to establish IQ.\n\n          -  Ability to provide written informed consent.\n\n        Prior Medication:\n\n        Required:\n\n          -  AZT for at least 12 weeks prior to study entry or any other approved antiretroviral\n             agent (i.e., ddI or ddC) for at least 8 weeks prior to study entry, except in\n             antiretroviral-intolerant patients who must be off antiretrovirals for at least 4\n             weeks.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n          -  Active symptomatic AIDS-defining opportunistic infection (maintenance therapy for\n             opportunistic infections, e.g., Pneumocystis carinii pneumonia, Mycobacterium avium\n             infection, and cytomegalovirus, is permitted).\n\n          -  Neoplasms other than basal cell carcinoma, in situ carcinoma of the cervix, or\n             Kaposi's sarcoma without evidence of visceral involvement or that do not require\n             systemic chemotherapy.\n\n          -  Confounding neurological disorders, including the following:\n\n          -  a) neurologic disease unrelated to HIV infection (such as multiple sclerosis,\n             documented stroke, degenerative disease); b) chronic seizure disorders or head\n             injuries if the condition results in functional impairment or is likely to interfere\n             with evaluations; c) central nervous system (CNS) infections or neoplasms (such as\n             toxoplasmosis, primary or metastatic CNS lymphoma, progressive multifocal\n             leukoencephalopathy, cryptococcal or other fungal meningitis, tuberculous CNS\n             infections, or untreated neurosyphilis).\n\n          -  Severe premorbid psychiatric illness including bipolar illness, schizophrenia, and\n             depression requiring electroconvulsive therapy.\n\n          -  Major depression likely to interfere with evaluation or protocol compliance.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Major psychotropic medication, including MAO inhibitors, phenothiazines,\n             butyrophenones, barbiturates, or amphetamines (unless a stable dose is maintained for\n             30 days prior to study entry).\n\n          -  Any ongoing maintenance therapy for confounding neurological disorders.\n\n        Patients with the following prior conditions are excluded:\n\n        Confounding neurological disorders defined in the \"Exclusion Co-existing Conditions\"\n        field.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Investigative drugs within 30 days prior to study entry.\n\n          -  Confounding calcium channel antagonists (such as nifedipine, verapamil, diltiazem,\n             and related drugs) within 4 weeks prior to study entry.\n\n        Active alcohol or drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "36", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000738", 
            "org_study_id": "ACTG 162", 
            "secondary_id": "11137"
        }, 
        "intervention": [
            {
                "intervention_name": "Nimodipine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Nimodipine", 
                "Zidovudine"
            ]
        }, 
        "keyword": [
            "Central Nervous System Diseases", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS Dementia Complex", 
            "AIDS-Related Complex", 
            "Zidovudine", 
            "Nimodipine"
        ], 
        "lastchanged_date": "March 30, 2012", 
        "link": {
            "description": "Click here for more information about Zidovudine", 
            "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=4"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "UCLA CARE Center CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana Univ. School of Medicine, Infectious Disease Research Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02118"
                    }, 
                    "name": "Bmc Actg Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess - East Campus A0102 CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "University of Minnesota, ACTU"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Washington U CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ. of Rochester ACTG CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Unc Aids Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Case CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington"
                    }, 
                    "name": "University of Washington AIDS CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1", 
        "overall_official": [
            {
                "last_name": "Lipton S", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Navia B", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Simpson D", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Tucker T", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "PMID": "9674806", 
                "citation": "Navia BA, Dafni U, Simpson D, Tucker T, Singer E, McArthur JC, Yiannoutsos C, Zaborski L, Lipton SA. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology. 1998 Jul;51(1):221-8."
            }, 
            {
                "citation": "Galgani S, Narciso P, Balestra P, Pigorini F, Pau F, Sette P, Tozzi V, Alba L, Grisetti S, Visco G. Nimodipine+ZDV vs ZDV in patients with ADC. Int Conf AIDS. 1994 Aug 7-12;10(1):205 (abstract no PB0248)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000738"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Miles", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Glaxo Wellcome", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2012"
    }, 
    "geocoordinates": {
        "Beth Israel Deaconess - East Campus A0102 CRS": "42.358 -71.06", 
        "Bmc Actg Crs": "42.358 -71.06", 
        "Case CRS": "41.499 -81.695", 
        "Indiana Univ. School of Medicine, Infectious Disease Research Clinic": "39.769 -86.158", 
        "Massachusetts General Hospital ACTG CRS": "42.358 -71.06", 
        "Northwestern University CRS": "41.878 -87.63", 
        "UCLA CARE Center CRS": "34.052 -118.244", 
        "Unc Aids Crs": "35.913 -79.056", 
        "Univ. of Rochester ACTG CRS": "43.161 -77.611", 
        "University of Minnesota, ACTU": "44.98 -93.264", 
        "University of Washington AIDS CRS": "47.606 -122.332", 
        "Washington U CRS": "38.627 -90.199"
    }
}